AlzeCure Pharma: New Data from AlzeCure Demonstrate Potential Disease-Modifying Effects of NeuroRestore ACD856

STOCKHOLM, SWEDEN / ACCESSWIRE / October 11, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule

Related Keywords

Sweden ,Stockholm ,Swedish ,Pontus Forsell ,Sanja Juric ,Alzecure Pharma ,Johan Sandin ,Cristina Parrado ,Head Of Research ,Brain Derived Neurotrophic Factor ,Nasdaq First North Premier Growth Market ,Nerve Growth Factor ,Alzecure ,Dharma ,Data ,Rom ,Emonstrate ,Potential ,Disease ,Modifying ,Effects ,Neurorestore ,Cd856 ,